UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. )*
Nurix Therapeutics Inc.
(Name of Issuer)
Common
Stock, par value $0.001 per share
(Title of Class of Securities)
67080M103
(CUSIP Number)
December 31, 2023
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which
this Schedule is filed:
x Rule 13d-1(b)
¨ Rule 13d-1(c)
¨ Rule 13d-1(d)
* The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any
subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required in the remainder of this
cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934
(“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).
CUSIP No. 67080M103 |
13G |
Page 2 of 5 Pages |
1. |
NAMES
OF REPORTING PERSONS |
|
|
ARK
Investment Management LLC |
|
|
|
|
2. |
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
|
|
(a) ☐ |
|
|
(b) ☐ |
|
|
3. |
SEC
USE ONLY |
|
|
|
|
|
|
|
4. |
CITIZENSHIP
OR PLACE OF ORGANIZATION |
|
|
Delaware,
United States |
|
|
|
|
NUMBER
OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH |
5. |
SOLE
VOTING POWER |
|
|
3,194,999
|
|
|
|
|
6. |
SHARED
VOTING POWER |
|
|
0 |
|
|
|
|
7. |
SOLE
DISPOSITIVE POWER |
|
|
3,194,999
|
|
|
|
|
8. |
SHARED
DISPOSITIVE POWER |
|
|
0 |
|
|
|
|
9. |
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
|
|
3,194,999
|
|
|
|
|
10. |
CHECK
IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |
|
|
☐ |
|
|
|
|
11. |
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9) |
|
|
6.59% |
|
|
|
|
12. |
TYPE
OF REPORTING PERSON |
|
|
IA |
|
|
|
|
|
|
|
|
|
|
CUSIP
No. 67080M103 |
13G |
Page 3
of 5 Pages |
Item 1(a) Name of issuer:
Nurix Therapeutics Inc.
Item 1(b) Address of issuer's
principal executive offices:
1700 Owens
Street, Suite 205
San Francisco,
CA 94158
Item 2(a) Name of person filing:
ARK Investment Management LLC
Item 2(b) Address or principal
business office or, if none, residence:
ARK Investment Management LLC
200 Central Avenue
St. Petersburg, FL 33701
Item 2(c) Citizenship:
Delaware, United States
Item 2(d) Title of class of
securities:
Common Shares, par value $0.001 per
share
Item 2(e) CUSIP No.:
67080M103
Item 3. If this statement is filed
pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a) ¨ Broker or dealer registered
under section 15 of the Act (15 U.S.C. 78o);
(b) ¨ Bank as defined in section
3(a)(6) of the Act (15 U.S.C. 78c);
(c) ¨ Insurance company as defined
in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d) ¨ Investment company registered
under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
(e) x An investment adviser in
accordance with § 240.13d-1(b)(1)(ii)(E);
(f) ¨ An employee benefit plan
or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g) ¨ A parent holding company
or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h) ¨ A savings associations
as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i) ¨ A church plan that is excluded
from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j) ¨ A non-U.S. institution
in accordance with § 240.13d-1(b)(1)(ii)(J);
(k) ¨ Group, in accordance with
§ 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the
type of institution: ____
CUSIP
No. 67080M103 |
13G |
Page 4
of 5 Pages |
Item 4. Ownership
(a) Amount
beneficially owned:
3,194,999
(b) Percent
of class:
6.59%
(c) Number
of shares as to which such person has:
(i) Sole
power to vote or to direct the vote: 3,194,999
(ii) Shared
power to vote or to direct the vote: 0
(iii) Sole
power to dispose or to direct the disposition of: 3,194,999
(iv) Shared
power to dispose or to direct the disposition of: 0
Item 5. Ownership of 5 Percent or
Less of a Class.
Not applicable.
Item 6. Ownership of More than 5 Percent on Behalf of Another Person.
To the knowledge of the Reporting Person,
no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, a number
of the shares which represents more than five percent of the number of outstanding class of the shares.
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not applicable.
Item 8. Identification and Classification of Members of the Group.
Not applicable.
Item 9. Notice of Dissolution of Group.
Not applicable.
CUSIP
No. 67080M103 |
13G |
Page 5
of 5 Pages |
Item 10. Certifications.
By signing below
I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course
of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the
issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that
purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
The reporting persons
agree that this statement is filed on behalf of each of them.
Dated: January 29,
2024
|
ARK Investment
Management LLC |
|
|
|
|
By: |
/s/ Kellen
Carter |
|
|
Name: |
Kellen Carter |
|
|
Title: |
Chief Compliance Officer |
Nurix Therapeutics (NASDAQ:NRIX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Nurix Therapeutics (NASDAQ:NRIX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024